{"id":"NCT01572038","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer","officialTitle":"A Multicenter, Open-Label, Single-Arm Study of Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2-Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06-01","primaryCompletion":"2019-09-20","completion":"2019-09-20","firstPosted":"2012-04-05","resultsPosted":"2020-09-25","lastUpdate":"2020-09-25"},"enrollment":1436,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Neoplasms"],"interventions":[{"type":"DRUG","name":"Docetaxel","otherNames":[]},{"type":"DRUG","name":"Nab-paclitaxel","otherNames":[]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"DRUG","name":"Pertuzumab","otherNames":["RO 43-68451"]},{"type":"DRUG","name":"Trastuzumab","otherNames":["Herceptin"]}],"arms":[{"label":"Pertuzumab + Trastuzumab + Taxane","type":"EXPERIMENTAL"}],"summary":"This multicenter, open-label, single-arm, Phase IIIb study will evaluate the safety and tolerability of pertuzumab in combination with trastuzumab (Herceptin) and a taxane (docetaxel, paclitaxel or nab-paclitaxel) in first-line treatment in participants with metastatic or locally recurrent HER2-positive breast cancer. Participants will receive pertuzumab intravenously (IV) and trastuzumab (Herceptin) IV plus a taxane in cycles of 3 weeks each until predefined study end, unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first.","primaryOutcome":{"measure":"Overview of the Number of Participants With at Least One Treatment-Emergent Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v4.0)","timeFrame":"From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.","effectByArm":[{"arm":"Pertuzumab + Trastuzumab + Taxane","deltaMin":1419,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":11},"locations":{"siteCount":299,"countries":["Algeria","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Ecuador","Egypt","Estonia","Finland","France","Germany","Greece","Hong Kong","Hungary","Israel","Italy","Lebanon","Lithuania","Mexico","Morocco","Netherlands","Pakistan","Peru","Poland","Portugal","Saudi Arabia","Serbia","Slovenia","Spain","Sweden","Turkey (TÃ¼rkiye)","Ukraine","United Arab Emirates","United Kingdom","Uruguay","Venezuela"]},"refs":{"pmids":["30796821"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":535,"n":1436},"commonTop":["Diarrhoea","Alopecia","Nausea","Fatigue","Asthenia"]}}